Olr515 inhibitors are a class of chemical compounds specifically designed to interact with and modulate the function of the olfactory receptor 515 (Olr515). These receptors belong to the larger family of G protein-coupled receptors (GPCRs), which play a crucial role in various cellular signaling pathways. Olr515, like other olfactory receptors, is primarily involved in detecting volatile molecules and contributing to the sense of smell. However, the modulation of this receptor by specific inhibitors can provide insights into its broader biological functions, as well as its role in intricate cellular networks. The inhibitors in this class are typically small molecules engineered to bind selectively to Olr515, altering its conformation and thus influencing the downstream signaling cascades initiated upon ligand binding.
The design and synthesis of Olr515 inhibitors involve a deep understanding of the receptor's structural biology and its interaction with endogenous ligands. Advanced techniques such as computational modeling, high-throughput screening, and structure-activity relationship (SAR) studies are employed to identify and refine these inhibitors. The binding affinity, selectivity, and structural properties of these inhibitors are often meticulously characterized using biochemical assays, molecular dynamics simulations, and various spectroscopic methods. Additionally, studies may focus on the conformational changes induced by these inhibitors at the molecular level, as well as their impact on the receptor's signaling efficacy and desensitization processes. By probing these molecular interactions, researchers can uncover valuable data about the dynamics of olfactory receptors and their broader implications within GPCR-related signaling pathways.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Afatinib-d4 | 850140-72-6 (unlabeled) | sc-481821 | 10 mg | $4665.00 | ||
Inhibits EGFR, HER2, and HER4, potentially affecting proteins in these signaling pathways. | ||||||
Bicalutamide | 90357-06-5 | sc-202976 sc-202976A | 100 mg 500 mg | $42.00 $146.00 | 27 | |
Androgen receptor antagonist, potentially affecting proteins in androgen signaling pathways. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Inhibits Src family kinases, potentially influencing proteins in cell signaling pathways. | ||||||
MDV3100 | 915087-33-1 | sc-364354 sc-364354A | 5 mg 50 mg | $245.00 $1051.00 | 7 | |
Androgen receptor inhibitor, potentially affecting proteins in androgen signaling pathways. | ||||||
Ibrutinib | 936563-96-1 | sc-483194 | 10 mg | $156.00 | 5 | |
Inhibits Bruton's tyrosine kinase, potentially affecting proteins in B-cell receptor signaling. | ||||||
Nilotinib | 641571-10-0 | sc-202245 sc-202245A | 10 mg 25 mg | $209.00 $413.00 | 9 | |
Inhibits BCR-ABL and c-KIT tyrosine kinases, potentially affecting proteins in associated signaling pathways. | ||||||
Olaparib | 763113-22-0 | sc-302017 sc-302017A sc-302017B | 250 mg 500 mg 1 g | $210.00 $305.00 $495.00 | 10 | |
PARP inhibitor, potentially affecting proteins involved in DNA repair pathways. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
Inhibits cyclin-dependent kinases 4 and 6, potentially affecting cell cycle-related proteins. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Inhibits multiple kinases, potentially affecting proteins in cell signaling and growth pathways. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $153.00 $938.00 | 5 | |
Multi-targeted tyrosine kinase inhibitor, potentially influencing proteins involved in angiogenesis and tumor growth. | ||||||